Table 4.
Plasma Cytokines (pg/mL) That Significantly Change After Cediranib Treatment in Patients With Recurrent Glioblastoma
| Biomarker | Pretreatment |
8 Hours |
Day 1 |
Day 9 |
Day 28 |
Day 56 |
Day 84 |
Day 112 |
||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | Interquartile Range | No. | P | Padj* | Median | Interquartile Range | No. | P | Padj* | Median | Interquartile Range | No. | P | Padj* | Median | Interquartile Range | No. | P | Padj* | Median | Interquartile Range | No. | P | Padj* | Median | Interquartile Range | No. | P | Padj* | Median | Interquartile Range | No. | P | Padj* | Median | Interquartile Range | No. | P | Padj* | |
| Plasma VEGF | 139 | 115-183 | 31 | NA | NA | 176 | 137-231 | 31 | < .001 | < .001 | 212 | 167-323 | 31 | < .001 | < .001 | 281 | 219-372 | 30 | < .001 | < .001 | 236 | 197-461 | 30 | < .001 | < .001 | 282 | 223-594 | 22 | < .001 | < .001 | 455 | 344-535 | 17 | < .001 | < .001 | 536 | 302-712 | 16 | < .001 | < .001 |
| Plasma PlGF | 21 | 17,25 | 31 | NA | NA | 35 | 30-45 | 31 | < .001 | < .001 | 58 | 40,77 | 31 | < .001 | < .001 | 79 | 47,128 | 30 | < .001 | < .001 | 69 | 49-121 | 30 | < .001 | < .001 | 94 | 59-169 | 22 | < .001 | < .001 | 135 | 100-185 | 17 | < .001 | < .001 | 161 | 70-244 | 16 | < .001 | < .001 |
| Plasma SDF1α | 1,602 | 1,301-1,977 | 30 | NA | NA | 1,621 | 1,344-2,169 | 30 | < .001 | < .001 | 1,729 | 1,491-2,338 | 31 | < .001 | < .001 | 1,886 | 1,326-2,240 | 30 | < .001 | .068 | 1,694 | 1,479-2,150 | 30 | .087 | .26 | 1,682 | 1,376-2,446 | 22 | .079 | .26 | 1,731 | 1,359-2,436 | 17 | .020 | .14 | 1,550 | 1,195-2,384 | 16 | .13 | .33 |
| Plasma sVEGFR2 | 7,917 | 6,556-10,334 | 31 | NA | NA | 8,051 | 6,226-10,026 | 31 | 0.72 | 0.72 | 8,188 | 6,147-10,062 | 31 | 0.42 | 0.72 | 6,854 | 5,068-8,773 | 30 | < .001 | < .001 | 5,486 | 3,986-6,451 | 30 | < .001 | < .001 | 4,950 | 4,044-6,717 | 22 | < .001 | < .001 | 4,276 | 3,404-5,551 | 17 | < .001 | < .001 | 4,338 | 3607,5823 | 16 | < .001 | < .001 |
| Plasma sTie2 | 9,970 | 7,770-12,085 | 31 | NA | NA | 9,650 | 7,785-11,057 | 31 | .49 | .69 | 10,050 | 7,960-12,330 | 31 | .69 | .69 | 8,610 | 6,670-9,862 | 30 | < .001 | < .001 | 8,120 | 7,002-10,540 | 30 | < .001 | < .001 | 7,810 | 7,271-9,964 | 22 | < .001 | .022 | 7,690 | 7,100-10,100 | 8 | < .001 | < .001 | 7,565 | 7,085-9,434 | 14 | < .001 | .012 |
| Plasma MMP-2 | 1,378 | 855-1,937 | 25 | NA | NA | 1,317 | 1,106-1,569 | 25 | .77 | .98 | 1,157 | 809-1,507 | 25 | < .001 | .020 | 1,135 | 737-1,594 | 25 | .034 | .30 | 1,183 | 789-1,590 | 25 | .32 | .98 | 1,172 | 920-1,344 | 19 | .41 | .98 | 1,108 | 990-1,627 | 15 | .98 | .98 | 1,188 | 937-1,977 | 10 | .84 | .98 |
| Plasma MMP-10 | 1.01 | 0.74-1.55 | 31 | NA | NA | 0.94 | 0.64-1.31 | 31 | < .001 | < .001 | 1.02 | 0.73-1.34 | 31 | .15 | .15 | 1.25 | 0.89,1.53 | 31 | .14 | .15 | 1.80 | 1.06-2.52 | 30 | < .001 | < .001 | 1.98 | 1.18-4.23 | 22 | < .001 | < .001 | 2.45 | 1.73,3.38 | 17 | < .001 | < .001 | 3.55 | 1.96-6.95 | 16 | < .001 | < .001 |
| Plasma Ang2 | 1,532 | 1,229-1,858 | 31 | NA | NA | 1,532 | 1,280-1,940 | 31 | .84 | .84 | 1,485 | 1,161-1,923 | 31 | .23 | .54 | 1,248 | 1,038-1,640 | 30 | < .001 | .018 | 1,226 | 1,008-1,660 | 30 | .016 | .14 | 1,341 | 952-2,106 | 22 | .17 | .53 | 1,409 | 1,037-1,757 | 17 | .043 | .34 | 1,346 | 1,090-1,714 | 14 | .17 | .52 |
NOTE. P indicates values that are from the paired exact Wilcoxon tests, unadjusted. Bold font indicates increase; italic font indicates decrease.
Abbreviations: VEGF, vascular endothelial growth factor; PlGF, placental growth factor; SDF1α, stromal cell–derived factor-1α; sVEGFR2, soluble VEGF receptor 2; sTie2, soluble Tek/Tie2 receptor; MMP, matrix metalloproteinase; Ang2, angiopoietin 2.
*
P values are from the paired exact Wilcoxon tests, adjusted to control the false discovery rate over time, with weights proportional to the square root of the number of the measurements.